Phathom Pharmaceuticals (PHAT) Stock Forecast, Price Target & Predictions
PHAT Stock Forecast
Phathom Pharmaceuticals stock forecast is as follows: an average price target of $25.83 (represents a 45.77% upside from PHAT’s last price of $17.72) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
PHAT Price Target
The average price target for Phathom Pharmaceuticals (PHAT) is $25.83 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $12.00. This represents a potential 45.77% upside from PHAT's last price of $17.72.
PHAT Analyst Ratings
According to 11 Wall Street analysts, Phathom Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for PHAT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (54.55%), 4 'Hold' (36.36%), 1 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).
Phathom Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | Paul Choi | Goldman Sachs | $12.00 | $11.75 | 2.13% | -32.28% |
| Jul 19, 2024 | Matthew Caufield | H.C. Wainwright | $28.00 | $10.95 | 155.82% | 58.01% |
| May 02, 2024 | Annabel Samimy | Stifel Nicolaus | $24.00 | $9.76 | 145.90% | 35.44% |
| Jan 05, 2024 | Joseph Stringer | Needham | $26.00 | $8.99 | 189.21% | 46.73% |
| Jan 04, 2023 | - | BMO Capital | $35.00 | $11.99 | 191.91% | 97.52% |
| Jan 04, 2023 | - | Needham | $25.00 | $11.99 | 108.51% | 41.08% |
| Nov 14, 2022 | - | BMO Capital | $38.00 | $10.65 | 256.81% | 114.45% |
| Nov 11, 2022 | - | Guggenheim | $30.00 | $10.78 | 178.29% | 69.30% |
The latest Phathom Pharmaceuticals stock forecast, released on Aug 08, 2024 by Paul Choi from Goldman Sachs, set a price target of $12.00, which represents a 2.13% increase from the stock price at the time of the forecast ($11.75), and a -32.28% decrease from PHAT last price ($17.72).
Phathom Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 4 |
| Avg Price Target | $12.00 | $20.00 | $22.50 |
| Last Closing Price | $17.72 | $17.72 | $17.72 |
| Upside/Downside | -32.28% | 12.87% | 26.98% |
In the current month, the average price target of Phathom Pharmaceuticals stock is $12.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a -32.28% decrease as opposed to Phathom Pharmaceuticals's last price of $17.72. This month's average price target is down -40.00% compared to last quarter, and down -46.67% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 08, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| Jul 19, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jan 05, 2024 | Needham | Buy | Buy | Hold |
| May 11, 2023 | William Blair | - | Market Perform | Downgrade |
| May 11, 2023 | RBC Capital | - | Outperform | Upgrade |
| May 11, 2023 | BTIG | - | Sell | Downgrade |
| May 11, 2023 | Piper Sandler | - | Neutral | Downgrade |
| May 11, 2023 | JMP Securities | - | Perform | Downgrade |
| May 11, 2023 | Goldman Sachs | - | Sell | Downgrade |
| May 11, 2023 | Evercore ISI | - | Outperform | Upgrade |
Phathom Pharmaceuticals's last stock rating was published by Goldman Sachs on Aug 08, 2024. The company gave PHAT a "Neutral" rating, the same as its previous rate.
Phathom Pharmaceuticals Financial Forecast
Phathom Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $682.00K | - |
| Avg Forecast | $54.50M | $44.75M | $39.27M | $26.43M | $22.37M | $12.61M | $5.68M | $1.63M | $400.89K | $211.00K |
| High Forecast | $58.78M | $48.26M | $42.35M | $28.50M | $24.12M | $13.49M | $6.13M | $1.76M | $432.37K | $225.41K |
| Low Forecast | $48.84M | $40.10M | $35.19M | $23.68M | $20.04M | $11.43M | $5.09M | $1.46M | $359.25K | $195.51K |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | - |
| Surprise % | - | - | - | - | - | - | - | - | 1.70% | - |
Phathom Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.63M, with a low forecast of $1.46M, and a high forecast of $1.76M. PHAT's average Quarter revenue forecast represents a 138.95% increase compared to the company's last Quarter revenue of $682.00K (Dec 23).
Phathom Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | - |
| EBITDA | - | - | - | - | - | - | - | - | $52.72M | $-37.78M |
| Avg Forecast | $32.70M | $26.85M | $23.56M | $15.86M | $13.42M | $7.57M | $3.41M | $977.79K | $240.54K | $-33.88M |
| High Forecast | $35.27M | $28.96M | $25.41M | $17.10M | $14.47M | $8.10M | $3.68M | $1.05M | $259.42K | $-27.11M |
| Low Forecast | $29.30M | $24.06M | $21.11M | $14.21M | $12.03M | $6.86M | $3.05M | $876.21K | $215.55K | $-40.66M |
| Surprise % | - | - | - | - | - | - | - | - | 219.18% | 1.11% |
1 analysts predict PHAT's average Quarter EBITDA for Mar 24 to be $977.79K, with a high of $1.05M and a low of $876.21K. This is -98.15% lower than Phathom Pharmaceuticals's previous annual EBITDA (Dec 23) of $52.72M.
Phathom Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | - |
| Net Income | - | - | - | - | - | - | - | - | $121.88M | $-43.42M |
| Avg Forecast | $-41.28M | $-48.60M | $-65.59M | $-75.74M | $-78.01M | $-85.92M | $-77.29M | $-77.33M | $-63.08M | $-36.47M |
| High Forecast | $-35.71M | $-42.04M | $-56.73M | $-65.51M | $-67.48M | $-80.63M | $-66.85M | $-66.89M | $-58.28M | $-29.18M |
| Low Forecast | $-45.50M | $-53.56M | $-72.28M | $-83.46M | $-85.97M | $-91.20M | $-85.18M | $-85.22M | $-67.87M | $-43.77M |
| Surprise % | - | - | - | - | - | - | - | - | -1.93% | 1.19% |
Phathom Pharmaceuticals's average Quarter net income forecast for Mar 24 is $-77.33M, with a range of $-85.22M to $-66.89M. PHAT's average Quarter net income forecast represents a -163.45% decrease compared to the company's last Quarter net income of $121.88M (Dec 23).
Phathom Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | - |
| SG&A | - | - | - | - | - | - | - | - | $57.00M | $20.25M |
| Avg Forecast | $1.93B | $1.58B | $1.39B | $935.09M | $791.35M | $446.14M | $200.97M | $57.66M | $14.18M | $7.47M |
| High Forecast | $2.08B | $1.71B | $1.50B | $1.01B | $853.48M | $477.44M | $216.74M | $62.19M | $15.30M | $7.98M |
| Low Forecast | $1.73B | $1.42B | $1.25B | $837.95M | $709.14M | $404.51M | $180.09M | $51.67M | $12.71M | $6.92M |
| Surprise % | - | - | - | - | - | - | - | - | 4.02% | 2.71% |
Phathom Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $57.66M, based on 1 Wall Street analysts, with a range of $51.67M to $62.19M. The forecast indicates a 1.17% rise compared to PHAT last annual SG&A of $57.00M (Dec 23).
Phathom Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | - |
| EPS | - | - | - | - | - | - | - | - | - | $-1.14 |
| Avg Forecast | $-0.70 | $-0.83 | $-1.12 | $-1.29 | $-1.33 | $-1.47 | $-1.32 | $-1.32 | $-1.08 | $-0.97 |
| High Forecast | $-0.61 | $-0.72 | $-0.97 | $-1.12 | $-1.15 | $-1.38 | $-1.14 | $-1.14 | $-1.00 | $-0.88 |
| Low Forecast | $-0.78 | $-0.91 | $-1.23 | $-1.43 | $-1.47 | $-1.56 | $-1.45 | $-1.46 | $-1.16 | $-1.05 |
| Surprise % | - | - | - | - | - | - | - | - | -0.00% | 1.18% |
According to 1 Wall Street analysts, Phathom Pharmaceuticals's projected average Quarter EPS for Mar 24 is $-1.32, with a low estimate of $-1.46 and a high estimate of $-1.14. This represents a -55124.17% decrease compared to PHAT previous annual EPS of - (Dec 23).
Phathom Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.72 | $70.00 | 9622.22% | Buy |
| XFOR | X4 Pharmaceuticals | $0.65 | $3.67 | 464.62% | Buy |
| IMMX | Immix Biopharma | $1.97 | $7.00 | 255.33% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.22 | $7.00 | 215.32% | Buy |
| INZY | Inozyme Pharma | $4.98 | $14.00 | 181.12% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.20 | $38.80 | 173.24% | Buy |
| GPCR | Structure Therapeutics | $36.95 | $83.67 | 126.44% | Buy |
| LYRA | Lyra Therapeutics | $0.27 | $0.50 | 85.19% | Hold |
| CGEM | Cullinan Oncology | $17.98 | $32.00 | 77.98% | Buy |
| TERN | Terns Pharmaceuticals | $7.81 | $12.50 | 60.05% | Buy |
| PHAT | Phathom Pharmaceuticals | $17.72 | $25.83 | 45.77% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.37 | $3.33 | 40.51% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $24.93 | $34.00 | 36.38% | Buy |
| BPMC | Blueprint Medicines | $86.43 | $101.50 | 17.44% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
PHAT Forecast FAQ
Is Phathom Pharmaceuticals a good buy?
Yes, according to 11 Wall Street analysts, Phathom Pharmaceuticals (PHAT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 54.55% of PHAT's total ratings.
What is PHAT's price target?
Phathom Pharmaceuticals (PHAT) average price target is $25.83 with a range of $12 to $35, implying a 45.77% from its last price of $17.72. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Phathom Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for PHAT stock, the company can go up by 45.77% (from the last price of $17.72 to the average price target of $25.83), up by 97.52% based on the highest stock price target, and down by -32.28% based on the lowest stock price target.
Can Phathom Pharmaceuticals stock reach $30?
PHAT's highest twelve months analyst stock price target of $35 supports the claim that Phathom Pharmaceuticals can reach $30 in the near future.
What is Phathom Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $12 price target for Phathom Pharmaceuticals (PHAT) this month, down -32.28% from its last price of $17.72. Compared to the last 3 and 12 months, the average price target increased by 12.87% and increased by 26.98%, respectively.
What are Phathom Pharmaceuticals's analysts' financial forecasts?
Phathom Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $42.28M (high $45.5M, low $38.02M), average EBITDA is $25.37M (high $27.3M, low $22.81M), average net income is $-319M (high $-282M, low $-348M), average SG&A $1.5B (high $1.61B, low $1.35B), and average EPS is $-5.44 (high $-4.813, low $-5.936). PHAT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $164.95M (high $177.9M, low $147.81M), average EBITDA is $98.97M (high $106.74M, low $88.69M), average net income is $-231M (high $-200M, low $-255M), average SG&A $5.84B (high $6.29B, low $5.23B), and average EPS is $-3.948 (high $-3.415, low $-4.351).
Did the PHAT's actual financial results beat the analysts' financial forecasts?
Based on Phathom Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $682K, beating the average analysts forecast of $400.89K by 70.12%. Apple's EBITDA was $-167M, missing the average prediction of $240.54K by -69657.99%. The company's net income was $0, missing the average estimation of $-63.075M by -100.00%. Apple's SG&A was $117.93M, beating the average forecast of $14.18M by 731.37%. Lastly, the company's EPS was $0, missing the average prediction of $-1.077 by -100.00%. In terms of the last quarterly report (Dec 2023), Phathom Pharmaceuticals's revenue was $682K, beating the average analysts' forecast of $400.89K by 70.12%. The company's EBITDA was $52.72M, beating the average prediction of $240.54K by 21818.13%. Phathom Pharmaceuticals's net income was $121.88M, missing the average estimation of $-63.075M by -293.22%. The company's SG&A was $57M, beating the average forecast of $14.18M by 301.82%. Lastly, the company's EPS was $0.0024, missing the average prediction of $-1.077 by -100.22%